Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2

Clinical-stage biotech Nouscom announced it has closed a $135 million Series D financing round that was oversubscribed. The capital will be used to move its lead cancer vaccine candidate into a Phase 2 clinical trial.

The funding round reflects strong investor interest in the company’s immunotherapy platform and provides resources for further development and regulatory work.

CEO Marina Udier expressed enthusiasm about the milestone, saying the additional capital brings the company closer to demonstrating the vaccine’s potential in patients.